Post-Test EGFR: The Challenge of Primary and Secondary Resistance Post-Test Which of the following EGFR alterations is generally associated with poor response to first- and second-generation TKI therapy compared to the others? Exon 18 p.G719X mutation Exon 19 deletions Exon 20 insertion mutation Exon 21 p.L858R substitution Which of the following statements regarding amivantamab is TRUE? Amivantamab is currently being assessed for the treatment of sensitizing EGFR mutations Amivantamab is under investigation with alectinib as a first-line treatment option in EGFR+ NSCLC In the CHRYSALIS study, treatment with amivantamab led to an ORR of 50% and a DOR of 12 months The most common adverse event with amivantamab use is is QTc prolongation With which agent is premedication with an antihistamine and antipyretic currently recommended with each dose to reduce the risk of common adverse events? Amivantamab Mobocertinib Osimertinib Sunvozertinib How confident are you in your ability to implement strategies to anticipate and address/mitigate the most common and serious adverse events associated with EGFR-targeted therapies in NSCLC? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
